Action of cyclooxygenase inhibitors and a leukotriene biosynthesis inhibitor on cisplatin-induced acute and delayed emesis in the ferret

Journal of Pharmacological Sciences

Volumn 103, Issue 2, 2007, Pages 189-200

  Sam, Tasia S W ^a   Ngan, Man P ^a   Riendeau, Denis ^b   Robichaud, Annette ^b   Rudd, John A ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Cisplatin; Cyclooxygenase; Dexamethasone; Emesis; Leukotriene

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; FURANONE DERIVATIVE; INDOMETACIN; LEUKOTRIENE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIEMETIC ACTIVITY; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; FERRET; NONHUMAN; RETCHING; SIGNAL TRANSDUCTION; VOMITING;

EID: 33847160825     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0061169     Document Type: Article

References (39)

1. Naylor RJ, Rudd JA. Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. Oncology. 1996;53 Suppl 1:8-17.
2. Kris MG, Pisters KM, Hinkley L. Delayed emesis following anticancer chemotherapy. Support. Care Cancer. 1994;2:297-300.
3. Rudd JA, Andrews PLR. Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. In: Hesketh PJ, editor. Management of nausea and vomiting in cancer and cancer treatment. London: Jones and Barlett Publishers Inc; 2004. p. 15-66.
4. 1 receptor in nausea and emesis. In: Holzer P, editor. Handbook of experimental pharmacology. Vol. 164, New York: Springer-Verlag; 2004. p. 359-441.
5. Gralla RJ, Rittenberg C, Peralta M, Lettow L, Cronin M. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Oncology. 1996;53 Suppl 1:86-91.
6. Sam TSW, Chan SW, Rudd JA, Yeung JH. Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol. 2001;417:231-237.
7. Ho C-M, Ho S-T, Wang J-J, Tsai SK, Chai CY. Dexamethasone has a central anti-emetic mechanism in decerebrate cats. Anesth Analg. 2004;99:734-739.
8. Rudd JA, Bunce KT, Naylor RJ. The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology. 1996;35:91-97.
9. Girod V, Bouvier M, Grélot L. Characterization of lipopolysaccharide-induced emesis in conscious piglets: effects of cervical vagotomy, cyclooxygenase inhibitors and a 5-HT(3) receptor antagonist. Neuropharmacol. 2000;39:2329-2335.
10. Wright A, Andrews PLR, Titball RW. Induction of emetic, pyrexic, and behavioral effects of Staphylococcus aureus enterotoxin B in the ferret. Infect Immun. 2000;68:2386-2389.
11. Scheuber PH, Denzlinger C, Wilker D, Beck G, Keppler D, Hammer DK. Staphylococcal enterotoxin B as a nonimmunological mast cell stimulus in primates: the role of endogenous cysteinyl leukotrienes. Int Arc Allergy App Immunol. 1987;82:289-291.
12. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998;47 Suppl 2:S78-S87.
13. Suzuki M, Ohwada M, Tamada T. Plasma prostaglandin levels in patients with gynecologic malignancies and its fluctuations during chemotherapeutically- induced gastrointestinal toxicity. Jpn J Clin Oncol. 1987;17:215-220.
14. Lau CK, Black WC, Belley M, Chan C, Charleson S, Denis D, et al. From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Adv Exp Med Biol. 1997;407:73-78.
15. Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-tbutyl-thio-5-isopropylindol-2- yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1989;67:456-464.
16. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997;121:105-117.
17. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther. 1996;274:1531-1537.
18. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 1994;4:17-23.
19. Empey LR, Walker K, Fedorak RN. Indomethacin worsens and a leukotriene biosynthesis inhibitor accelerates mucosal healing in rat colitis. Can J Physiol Pharmacol. 1992;70:660-668.
20. Sam TSW, Kan KKW, Ngan MP, Rudd JA, Yeung HKJ. Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol. 2003;466:163-168.
21. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
22. Batt DG. 5-lipoxygenase inhibitors and their anti-inflammatory activities. Prog Med Chem. 1992;29:1-63.
23. Kan KKW, Jones RL, Ngan MP, Rudd JA. Action of prostanoids to induce emesis and defecation in the ferret. Eur J Pharmacol. 2002;453:299-308.
24. 2 in the ferret. Eur J Pharmacol. 2006;544:153-159.
25. Wallace JL. The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage - potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol. 1994;72:1493-1498.
26. Allan SG, Smyth JF. Small intestinal mucosal toxicity of cis-platinum - comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer. 1986;53:355-360.
27. Yanez JA, Teng XW, Roupe KA, Fariss MW, Davies NM. Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase-2. J Pharm Pharmaceut Sci. 2003;6:308-314.
28. Bhargava KP, Chandra OM, Verma DR. The mechanism of the emetic action of sodium salicylate. Br J Pharmacol. 1963;21:45-50.
29. Tanihata S, Oda S, Nakai S, Uchiyama T. Antiemetic effect of dexamethasone on cisplatin-induced early and delayed emesis in the pigeon. Eur J Pharmacol. 2004;484:311-321.
30. Girod V, Dapzol J, Bouvier M, Grélot M. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets. Neuropharmacol. 2002;42:428-436.
31. Pairet M, Van Ryn J. Tests for cyclooxygenase-1 and -2 inhibition. In: Vane J, Botting R. editors. Clinical significance and potential of selective COX-2 inhibitors. London: William Harvey Press; 1998. p. 19-30.
32. Depre M, Friedman B, Tanaka W, van Hecken A, Buntinx A, DeSchepper P. Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans. Clin Pharmacol Ther. 1993;53:602-607.
33. Rudd JA, Naylor RJ. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol. 1996;118:209-214.
34. Boughton-Smith NK, Deakin AM, Follenfant RL, Whittle BJ, Garland LG. Role of oxygen radicals and arachidonic acid metabolites in the reverse passive Arthus reaction and carrageenin paw oedema in the rat. Br J Pharmacol. 1993;110:896-902.
35. Higgs GA, Mugridge KG, Moncada S, Vane JR. Inhibition of tissue damage by the arachidonate lipoxygenase inhibitor BW755C. Proc Nat Acad Sci U S A. 1984;81:2890-2892.
36. Kirchner T, Argentieri DC, Barbone AG, Singer M, Steber M, Ansell J, et al. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997;282:1094-1101.
37. Meurer R, Opas EE, Humes JL. Effects of cyclooxygenase and lipoxygenase inhibitors on inflammation associated with oxazolone-induced delayed hypersensitivity. Biochem Pharmacol. 1988;37:3511-3514.
38. Yamakuni H, Nakayama H, Matsui S, Imazumi K, Matsuo M, Mutoh S. Inhibitory effect of zacopride on cisplatin-induced delayed emesis in ferrets. J Pharmacol Sci. 2006;101:99-102.
39. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004;500:51-62.